Clinical trial NCT01905124: Safety &Efficacy of CF101 to Subjects With Uveitis
Official title: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Uveitis, Posterior
Uveitis, Intermediate
Keywords: Uveitis
Intermediate uveitis
Posterior uveitis
Lead sponsor: Can-Fite BioPharma
Sponsor class: INDUSTRY
First posted: 2013-07-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.

Detailed description: This is a Phase 2, randomized, double-masked, placebo-controlled study in adult males and females, aged 18 years and over, with active, sight-threatening, noninfectious intermediate or posterior uveitis. Subjects will be randomly assigned to receive CF101 1 mg or matching placebo tablets in a 2:1 ratio orally every 12 hours for 24 weeks.

At the Screening Visit (performed within 4 weeks prior to Baseline), subjects who provide written informed consent will have a complete medical history, medication history, physical examination, weight, sitting blood pressure, pulse rate, temperature, electrocardiogram (ECG), clinical laboratory tests, and ophthalmologic examination, including biomicroscopy and grading of uveitis activity. For assessment of uveitis activity and response to treatment, fundus photography will be obtained according to a standardized procedure and interpreted at the Uveitis Photograph Reading Center.

Subjects who successfully qualify will begin dosing with CF101 1 mg or placebo, to be taken orally every 12 hours for 24 weeks. At the Baseline Visit, a PBMC sample will be obtained for assessment of A3AR expression level. Subjects will return for safety and efficacy assessments and a new supply of study medication at Weeks 2, 4, 8, 12, 16, 20, and for final assessment and discharge at Week 24. A telephone call to each subject will be made at Week 26, for the purpose of collecting information on adverse events (AEs) and concomitant medications.

During the course of the trial, concomitant use of intraocular or posterior subtenon corticosteroids, intravitreal injections (including but not limited to steroids or anti-vascular endothelial growth factors), systemic corticosteroids at a dose \>20 mg/day prednisone equivalent, or monoclonal antibody therapy is prohibited. Systemic corticosteroid and immunosuppressive regimens must remain stable throughout the course of the trial.

Eligibility criteria: Inclusion Criteria:

1. Male or female, 18 years of age and over;
2. Diagnosis of active, sight-threatening, noninfectious intermediate or posterior uveitis, as determined by the Standardization of Uveitis Nomenclature (SUN) Working Group Criteria.
3. Vitreous haze in at least 1 eye (the "study eye") of ≥Grade 3 on the "Miami Scale" at the Screening Visit, as confirmed by the Uveitis Photograph Reading Center; ,
4. Best corrected visual acuity (BCVA) in the poorer seeing eye of 1.3 logarithm of the minimum angle of resolution (logMAR) or better by Early Treatment Diabetic Retinopathy Study (ETDRS; equivalent to 20/400) at Screening;
5. Requires, in the judgment of the Investigator, systemic therapy to treat uveitis;
6. No plans for elective ocular surgery during the trial duration;

10. Ability to understand and provide written informed consent.

Exclusion Criteria:

1. Primary diagnosis of anterior uveitis;
2. Uveitis of infectious etiology;
3. Presence of chorioretinal scars that are highly suspicious for ocular toxoplasmosis;
4. Confirmed or suspected uveitis of traumatic etiology;
5. Clinically suspected or confirmed central nervous system or ocular lymphoma;
6. Presence of any other form of ocular malignancy in the either eye including choroidal melanoma;
7. Corneal or lens opacities or obscured ocular media other than vitreous haze upon enrollment such that reliable clinical evaluations and grading of the posterior segment cannot be performed;
8. Pupillary dilation inadequate for quality fundus photography;
9. Uncontrolled glaucoma or ocular hypertension in either eye, defined as intraocular pressure (IOP) \>21 mm Hg while on medical therapy;
10. Chronic hypotony (IOP \<6 mm Hg) in either eye;
11. Presence of an ocular implantable steroid-eluting device;
12. Ocular injection of corticosteroid within 3 months prior to Baseline;
13. Use of Retisert within 6 months prior to baseline;
14. Use of the following within 90 days prior to Baseline or anticipated use to either eye during the trial:

    1. Intravitreal injections (including but not limited to steroids or anti-vascular endothelial growth factors), or
    2. Posterior subtenon steroids;
15. YAG capsulotomy within 30 days prior to Day 1 in the study eye;
16. History of herpetic infection in the study eye or adnexa;
17. Oral corticosteroid dose \>20 mg/day prednisone equivalent;
18. Oral corticosteroid dose has been changed within 2 weeks prior to screening, or is expected to change while on study;
19. Systemic immunosuppressive agent dose has been changed within 2 weeks prior to screening;
20. Treatment with systemic monoclonal antibody within the longer of 1 month or 5 serum half-lives, prior to screening;
21. Diagnosis or history of Behçet's Disease;
22. Any significant ocular disease that could compromise vision in either eye, including but not limited to:

    1. Diabetic retinopathy: proliferative diabetic retinopathy or non-proliferative diabetic retinopathy that compromise vision,
    2. Wet age-related macular degeneration, and
    3. Myopic degeneration with active subfoveal choroidal neovascularization.

Primary outcomes:
measure: Severity of uveitis on standardized photographic assessment
timeFrame: 24 weeks
Secondary outcomes:
measure: Safety of CF101
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Bnei-Zion Medical Center
Study officials:
References: